Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersJack Lief

David Schull, PresidentPresident and CEO

david.schull@russopartnersllc.com212.845.4271Cindy McGeeManager, IR and Corporate Communications

Anthony J. Russo, Ph.D., CEO858.453.7200, ext. 1479

tony.russo@russopartnersllc.com212.845.4251www.arenapharm.com
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... York , August 4, 2015 ... titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, ... Others) - Global Industry Analysis, Size, Volume, Share, Growth, ... According to a new market report published by Transparency ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ...
(Date:8/4/2015)... 04, 2015 Research ... addition of Jain PharmaBiotech,s new report "Animal ... their offering. This report describes and ... medicine and pharmaceuticals as well as improvement in ... in the application of biotechnology to manage genetic ...
(Date:8/4/2015)... Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) today reported ... June 30, 2015 and updated its financial guidance for ... this morning, August 4, 2015, at 10:30 AM ET. ... by dialing (855) 582-8078. The conference ID is 90889796. ... revenues of $38.3 million, an increase of 118% as compared ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 4ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 5ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 6ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 7ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 8ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 9ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 10ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 11ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 12ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 13ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 14ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 15ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 16
... Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company ... therapeutic agents for the treatment of Alzheimer,s and ... filed a response and request for continued examination ... 10/084,380, one of several applications pending in the ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... chief financial officer, will present an overview of the ... The VIVUS presentation will take place at the ... at 9:30 a.m. MST.  A live webcast and 30-day ...
Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3
(Date:8/4/2015)... ... August 04, 2015 , ... It’s hard to look your ... Spa in Santa Barbara, CA is offering the solution by offering an underarm ... sweat and odor glands in the underarms. This simple and permanent solution usually ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... Kingdom and other international locations have shown a rise in binge drinking among ... link between binge drinking and depression, are continuing to examine trends and evidence ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... They say ... better understand certain health conditions, pictures and medical art can be essential. StayWell, a ... providers. , Krames Patient Education solutions have been used by physicians and other ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... that Bruce McCalley joins its executive leadership team as Senior Vice President of ... at technology companies and expanding global markets with a special emphasis on the ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... nursing homes and other long-term care facilities, today announced details of the Advanced ... nursing homes and centers. , Providigm’s QAPI Accreditation program , introduced in ...
Breaking Medicine News(10 mins):Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3
... with thousands of,herb-loving individuals, organizations and businesses across ... tomorrow, Oct. 13. The company will,continue to celebrate ... free 28-ct Mega Men(R) or Women,s Ultra Mega(R) ... National Herb Day recognizes the importance of ...
... the solution to providing ... STORRS, Conn., Oct. 12 A new report released,today ... low health,literacy to the United States economy is in the ... report, Low Health Literacy:,Implications for National Health Policy, the savings ...
... (Nasdaq: ARAY ), a global leader in the ... for its first quarter fiscal,year 2008, ending September 29, ... A conference call to review the results will ... be hosted by Euan S. Thomson, Ph.D., president and,chief ...
... might fight deadly pulmonary disease, experts say , , FRIDAY, Oct. ... cholesterol also slow the lung function loss that inevitably occurs ... researchers report. , The Harvard study included a group of ... at least twice between 1995 and 2005. , Those who ...
... be good for lowering cholesterol and maybe even fighting ... appear to slow decline in lung function in the ... in Boston, it may be statins anti-inflammatory and antioxidant ... were published in the second issue for October in ...
... Feeds the Soul and Whets the Appetite, RALEIGH, ... this weight-loss support group turned relay team, wondered what,their ... would be. Maria,Fernandez and the members of TeamGDT thought ... for the Cure", was a great answer,to not only ...
Cached Medicine News:Health News:GNC Honors Herb Day Tomorrow (and All Month Long) 2Health News:New Report Estimates Cost of Low Health Literacy Between $106 - $236 Billion Annually 2Health News:New Report Estimates Cost of Low Health Literacy Between $106 - $236 Billion Annually 3Health News:Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results 2Health News:Anti-Cholesterol Drugs Help Prevent Lung Decline 2Health News:Statins reduce loss of function, keeping old lungs young - even in smokers 2Health News:Good Food. Good Friends. Great Cause. 2
... Sirolimus-eluting Coronary Stent consists of ... "sirolimus", a controlled-release polymer, and ... Upon placement, sirolimus elutes into ... the process of neointimal hyperplasia, ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Forte Guide Wire w/Markers: Front line use, 1:1 torque, excellent steering and tracking, sharp vessel images, floppy and moderate support....
Forte Guide Wire w/Markers: Front line use, 1:1 torque, excellent steering and tracking, sharp vessel images, floppy and moderate support....
Medicine Products: